Addiction Treatment
Addiction Treatment RSS Feed RSS

RESEARCH UPDATE

Antipsychotics for Methamphetamine Psychosis

January 18, 2022
Sanya Virani, MD.
Sanya Virani, MD. Dr. Virani has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
In this network meta-analysis, researchers compared different antipsychotics head-to-head for the treatment of methamphetamine psychosis and found some clear winners are losers.
Read More

Meds for Alcohol Use Disorders

January 18, 2022
Mikveh Warshaw, NP.
Mikveh Warshaw, NP. Ms. Warshaw has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Naltrexone has shown efficacy for the treatment of alcohol use disorder in tightly controlled trials. Here, researchers demonstrate the efficacy of naltrexone in a large scale naturalistic study.
Read More

Buprenorphine Treatment

November 5, 2021
Noah Capurso, MD
Noah Capurso, MDNoah Capurso, MD

Assistant Professor of Psychiatry at Yale University, CT. Editor-in-chief of The Carlat Addiction Treatment Report.

Dr. Capurso has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Buprenorphine is a first line medication for the treatment of opioid use disorder yet remains vastly under-prescribed. Here, Dr. Capurso reviews the pharmacologic principles relevant to buprenorphine prescribing and lays out how to start patients on the medication both in the clinic and at home.
Read More

Drug Overdoses in the US: Trends and Prevention Strategies

November 5, 2021
Joshua Sharfstein, MD
Joshua Sharfstein, MDJoshua Sharfstein, MD

Professor of the Practice of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

Dr. Sharfstein has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Increases in drug overdose mortality continues unabated around the country driven by widespread availability of illicit fentanyl and methamphetamines. Dr. Sharfstein provides context to these concerning trends and discusses prevention and harm reduction strategies clinicians can implement for their patients.
Read More

Suicide Safety Planning for the Patient with Addiction

November 5, 2021
Jessica Casella, LCSW
Jessica Casella, LCSW Private practice social worker, Branford, CT. Adjunct faculty member at Sacred Heart University School of Social Work. Active member of the state of Connecticut’s Suicide Advisory Board. Ms. Casella has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Addiction is a major risk factor for suicide. Here, we provide a practical guide to Safety Planning, an evidenced based approach for reducing suicide risk that can be implemented in a variety of clinical settings.
Read More

A New Buprenorphine Dosing Strategy for Easier Induction From Fentanyl

November 5, 2021
Oluwole Jegede, MD, PhD
Oluwole Jegede, MD. Dr. Jegede has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Avoiding buprenorphine induced withdrawal during induction can be particularly tricky for those using fentanyl. Researchers describe a novel induction dosing strategy that mitigates this risk.
Read More

Buprenorphine Induction Without Withdrawal

November 5, 2021
David Moltz, MD.
David Moltz, MD. Dr. Moltz has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Making the switch from full opioid agonist to buprenorphine usually involves a period of withdrawal prior to starting the medication. Here, researchers describe a method of switching from full to partial opioid agonist by using small “microdoses” in order to avoid withdrawal.
Read More

Suboxone vs. Vivitrol for Opioid Use Disorder: How Do you Choose?

November 5, 2021
Gregory Lande, MD.
Gregory Lande, MD. Dr. Lande has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Buprenorphine and long acting injectable naltrexone are both effective for the treatment of opioid use disorder; however, until now, we had little data to predict which patients would do better on which medications. Here, researchers identify patient characteristics predictive of success on buprenorphine versus naltrexone.
Read More
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
Featured Video
Featured Podcast
Recommended

About

Shop Online

Newsletters

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.